Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2
- PMID:14754410
- DOI: 10.2174/1568011043482205
Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2
Abstract
ABCG2, also termed BCRP/MXR/ABCP, is a half ATP-binding cassette (ABC) transporter expressed on plasma membranes. ABCG2 was independently cloned from placenta as well as cell lines selected for resistance to mitoxantrone or anthracyclines. ABCG2 consists of a nucleotide-binding domain (NBD) at the amino terminus and a transmembrane domain (TMD) at the carboxyl terminus and it is postulated to form a homodimer to perform its biological functions. Over-expression of ABCG2 in cell lines confers resistance on a wide variety of anticancer drugs including mitoxantrone, daunorubicin, doxorubicin, topotecan and epirubicin. The expression of ABCG2 has been implicated in multidrug resistance (MDR) of acute myeloid leukemia and some solid tumors. In addition, ABCG2 can transport several fluorescent dyes or toxins. ABCG2 is found to be expressed in epithelial cells of intestine and colon, liver canaliculi, and renal tubules, where it serves to eliminate the plasma level of orally administered anticancer drugs as well as ingested toxins. ABCG2 is found to be highly expressed in placenta and the luminal surface of microvessel endothelium blood-brain barrier where it may play a role in limiting the penetration of drugs, such as topotecan from the maternal plasma into the fetus and from blood to brain. A variety of inhibitors for ABCG2 including GF120918 may prove useful for sensitizing cancer cells to chemotherapy or altering the distribution of orally administered drug substrates of ABCG2. Interestingly, ABCG2 is also expressed highly in hematopoietic stem cells. However, the function of ABCG2 in stem cells is currently unknown, although it may provide protection to stem cells from a variety of xenobiotics.
Similar articles
- Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, Ashby CR Jr, Huang Y, Robey RW, Liang YJ, Chen LM, Shi CJ, Ambudkar SV, Chen ZS, Fu LW.Dai CL, et al.Cancer Res. 2008 Oct 1;68(19):7905-14. doi: 10.1158/0008-5472.CAN-08-0499.Cancer Res. 2008.PMID:18829547Free PMC article.
- Role of the breast cancer resistance protein (ABCG2) in drug transport.Mao Q, Unadkat JD.Mao Q, et al.AAPS J. 2005 May 11;7(1):E118-33. doi: 10.1208/aapsj070112.AAPS J. 2005.PMID:16146333Free PMC article.
- Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).Doyle L, Ross DD.Doyle L, et al.Oncogene. 2003 Oct 20;22(47):7340-58. doi: 10.1038/sj.onc.1206938.Oncogene. 2003.PMID:14576842Review.
- Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, Schinkel AH.Jonker JW, et al.J Natl Cancer Inst. 2000 Oct 18;92(20):1651-6. doi: 10.1093/jnci/92.20.1651.J Natl Cancer Inst. 2000.PMID:11036110
- Human multidrug transporter ABCG2, a target for sensitizing drug resistance in cancer chemotherapy.Xu J, Peng H, Zhang JT.Xu J, et al.Curr Med Chem. 2007;14(6):689-701. doi: 10.2174/092986707780059580.Curr Med Chem. 2007.PMID:17346156Review.
Cited by
- Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment.Zhang JT, Liu Y.Zhang JT, et al.Cancer Treat Rev. 2007 Dec;33(8):741-56. doi: 10.1016/j.ctrv.2007.07.018. Epub 2007 Sep 12.Cancer Treat Rev. 2007.PMID:17854999Free PMC article.Review.
- Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up.Agarwal S, Hartz AM, Elmquist WF, Bauer B.Agarwal S, et al.Curr Pharm Des. 2011;17(26):2793-802. doi: 10.2174/138161211797440186.Curr Pharm Des. 2011.PMID:21827403Free PMC article.Review.
- Benzanilide-Biphenyl Replacement: A Bioisosteric Approach to Quinoline Carboxamide-Type ABCG2 Modulators.Ochoa-Puentes C, Bauer S, Kühnle M, Bernhardt G, Buschauer A, König B.Ochoa-Puentes C, et al.ACS Med Chem Lett. 2013 Mar 4;4(4):393-6. doi: 10.1021/ml4000832. eCollection 2013 Apr 11.ACS Med Chem Lett. 2013.PMID:24900683Free PMC article.
- Bisphenol A at low nanomolar doses confers chemoresistance in estrogen receptor-alpha-positive and -negative breast cancer cells.Lapensee EW, Tuttle TR, Fox SR, Ben-Jonathan N.Lapensee EW, et al.Environ Health Perspect. 2009 Feb;117(2):175-80. doi: 10.1289/ehp.11788. Epub 2008 Oct 8.Environ Health Perspect. 2009.PMID:19270784Free PMC article.
- Photochemical internalisation of chemotherapy potentiates killing of multidrug-resistant breast and bladder cancer cells.Adigbli DK, Wilson DG, Farooqui N, Sousi E, Risley P, Taylor I, Macrobert AJ, Loizidou M.Adigbli DK, et al.Br J Cancer. 2007 Aug 20;97(4):502-12. doi: 10.1038/sj.bjc.6603895. Epub 2007 Jul 31.Br J Cancer. 2007.PMID:17667930Free PMC article.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources